Stemline
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Stemline and buy or sell other stocks, ETFs, and their options commission-free!About STML
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.
CEOIvan Bergstein, MD
CEOIvan Bergstein, MD
Employees—
Employees—
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2003
Founded2003
Employees—
Employees—
STML Key Statistics
Market cap621.20M
Market cap621.20M
Price-Earnings ratio-7.47
Price-Earnings ratio-7.47
Dividend yield—
Dividend yield—
Average volume2.51M
Average volume2.51M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$18.22
52 Week high$18.22
52 Week low$3.21
52 Week low$3.21
Stock Snapshot
As of today, Stemline(STML) shares are valued at $11.83. The company's market cap stands at 621.2M, with a P/E ratio of -7.47.
Stemline(STML) stock opened on 2025-12-17 at —. The price climbed to — and dipped to —.
Stemline(STML) shares are trading with a volume of 0, against a daily average of 2.51M.
In the last year, Stemline(STML) shares hit a 52-week high of $18.22 and a 52-week low of $3.21.
In the last year, Stemline(STML) shares hit a 52-week high of $18.22 and a 52-week low of $3.21.
People also own
Based on the portfolios of people who own STML. This list is generated using Robinhood data, and it’s not a recommendation.